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Abstract
Three distinct isolates of Candida albicans were used to establish systemic and oral infections in inbred mice that are genetically resistant or
susceptible to tissue damage. Patterns of infection differed significantly between both yeasts and mouse strains. Systemic infection conferred
significant protection against re-challenge with the homologous, but not the heterologous yeast; however, the protective effect was more evident
in the tissue-susceptible CBA/CaH mice than in the resistant BALB/c strain. In contrast, oral infection induced protection against both homol-
ogous and heterologous oral challenge, although this was significant only in the CBA/CaH mice. CBA/CaH mice produced antibodies of both
IgG1 and IgG2a subclasses, whereas BALB/c mice produced predominantly IgG1. Western blotting demonstrated considerable differences be-
tween epitopes recognised by serum antibodies from mice of both strains after immunisation with each of the three yeasts. Thus, different strains
of yeast show considerable specificity in antibody responses elicited by either systemic or oral infection.
 2005 Elsevier SAS. All rights reserved.
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Candida albicans is a common commensal that causes both
mucocutaneous and disseminated infections, particularly in
those who are debilitated or immunocompromised. Inbred
mice differ in their susceptibility to systemic infection with
the yeast [1e3], and some progress has been made in identify-
ing the genetic basis of these differences [4e6]. In oral candi-
diasis, the increased tissue susceptibility of CBA/CaH mice
relative to BALB/c has been confirmed [7], and DBA/2 mice
show slightly different patterns of oral colonisation compared
to BALB/c [8,9]. However, the extent to which host responses
are related to global virulence properties of different Candida
strains has not yet been evaluated.
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doi:10.1016/j.micinf.2005.08.011Clinical isolates of the yeast differ in virulence for mice, as
demonstrated by variations in patterns of mortality and fungal
burden after systemic challenge. A virulent isolate from
a patient with vaginal candidiasis showed higher colonisation
of the oral mucosa, and a stronger ability to cause disruption
of keratin than did a strain from transient candidaemia [10],
and wild-type strains have been shown to differ in their ability
to cause tissue damage in the absence of quantitative differen-
ces in infection [11]. Active regulation of enzyme secretion
may result in increased virulence, and high-proteinase isolates
were significantly more pathogenic for mice [12], but the
increased virulence was not associated with a single molecular
type or category identifiable through DNA fingerprinting or
pulsed-field electrophoretic karyotype. Secretory aspartyl pro-
teinases (SAPs) have been implicated in infection of the oral
mucosa [13], but no differences were detected in the ability
of SAP knockout strains to invade the stomach, or to dissem-
inate to internal organs such as the brain [14], indicating that
individual SAPs participated in, but were not essential for vir-
ulence. Some of these differences may be attributable to the
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models, whereas others may be related to the specific viru-
lence factors that are expressed under various conditions,
either in vivo or in vitro.
Recovery from primary Candida infection is attributed to
the actions of both T cells and phagocytes [15], but antibodies
play a dominant role in protection against secondary chal-
lenge. Monoclonal and polyclonal antibodies to C. albicans
can protect against both systemic and oral candidiasis
[16,17], although antibodies with defined specificities show
different degrees of protection [18e20]. B-cell epitope recog-
nition and antibody isotype also differ markedly between
inbred strains of mice, in that BALB/c mice produced high
levels of IgG1, whereas CBA/H produced predominantly
IgG2a [21].
The aims of this study were to compare the virulence of
three clinical isolates of C. albicans in mouse models of sys-
temic and oral candidiasis, to examine the role of antibody
in the protection of susceptible or resistant inbred mice against
systemic and oral challenge, and to identify patterns of epitope
recognition by serum antibody from these mice.
2. Materials and methods
2.1. Mice
Inbred female mice were purchased from the Animal
Resource Centre, Western Australia. Mice were kept in filter
top cages in a PC2 facility, and given food and water ad
libitum. Animal experiments were approved by the Animal
Experimentation Ethics Committee of the University of
Queensland, and carried out in accordance with the National
Health and Medical Research Council’s Australian Code of
Practice for Care and Use of Animals for Scientific Purposes
(1997).
2.2. Yeasts
Candida albicans isolates 3630 and 3683 were obtained
from the Australian Medical Mycology Reference Laboratory
(AMMRL) at the Royal North Shore Hospital, Sydney. Strain
3630 was from the nail of a patient with cutaneous candidiasis,
and 3683 was an oral isolate. C. albicans SC5314, isolated
from a patient with disseminated candidiasis [22], was a gift
from Dr P. Sundstrom, Ohio State University. Yeasts were
stored at 70 C in 15% (v/v) glycerol in Sabouraud’s broth
and grown in Sabouraud’s broth for 48 hours at room temper-
ature with continuous agitation.
2.3. Oral infection
Oral inoculation of yeast, and the swabbing procedures were
performed under halothane anaesthesia (Veterinary Companies
of Australia, Artarmon, NSW, Australia) using an inhalation
apparatus (Fluortec, Mediquip, Brisbane, Qld, Australia) and
a scavenging system (Omnicon Fresh Air Cannister, BickfordInc, NY, USA). Mice were inoculated with 1  108 yeasts in
20 ml sterile PBS, and infection monitored by swabbing the
oral cavity using sterile cotton ear, nose and throat (ENT)
swabs (Sarstedt, Adelaide, SA, Australia) and plating on
Sabouraud’s agar plates (MicroDiagnostics, Qld, Australia).
The plates were incubated at 37 C for 48 h and colony-
forming units (CFU) counted. The results were expressed
according the following scoring system [23]: Score 0 ¼ no
detectable yeasts; Score 1 ¼ 1e10 CFU; Score 2 ¼ 11e
100 CFU; Score 3 ¼ 110e1000 CFU; Score 4 ¼ 1000þ CFU.
2.4. Systemic infection
Mice were injected with 3  105 C. albicans 3630 and 3683
but 4  104 SC5314, in 200 ml PBS via the tail vein. A
reduced concentration was used for SC5314, because prelim-
inary experiments showed that mice inoculated with 3  105
cells died within 1 week of injection (data not shown). Where
necessary for comparisons between yeasts, the dose for 3630
and 3683 was also reduced to 4  104. Mice were killed on
day 5 after either primary infection or secondary challenge.
The brains and kidneys were harvested, weighed, suspended
in 1 ml sterile PBS, and homogenised. One hundred micro-
litres of suspension was titrated in duplicate on Sabouraud’s
agar plates, incubated at 37 C for 48 h, and colonies counted.
The results were expressed as log10 colony-forming units per
gram of tissue. For immunisation, mice were inoculated as
above. At week 6, they were challenged with 3  105 yeasts
and killed on day 5 for assessment of CFU in the brain and
kidneys as described above.
2.5. Extraction of Candida antigen
Yeasts were grown for 48 h at room temperature. 1  109
cells were harvested and washed twice with 10 ml sterilised
distilled water. The yeast pellet was resuspended in an equal
volume of Protein Extraction Buffer and mixed with an equal
volume of 0.4 mm glass beads. The yeasts were vortexed for
15 min at 4 C, after which 1 ml of 0.1% SDS was added while
vortexing for 1 min to ensure complete cell lysis. The protein
extract was collected by centrifuging at 2000 rpm for 20 min,
and stored at 70 C until used. The concentration of antigen
was estimated using BCA Protein Assay Kit (Pierce Chemical,
Rockford, IL, USA) according to the manufacturer’s
instructions.
2.6. SDSePAGE and Western blotting
SDSePAGE and immunoblotting were performed accord-
ing to manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA, USA). Briefly, the proteins were prepared in
a sample buffer and electrophoresed on a 7.5% SDSePAGE
gel after heating for 5 min at 95 C, and then transferred
onto a 0.2 mm nitrocellulose membrane (Bio-Rad) for antibody
binding. The concentration of antigens for SDSePAGE was
20 mg in 20 ml sample buffer/well. A pre-stained precision
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electrophoresed in parallel with the antigens.
2.7. Collection of immune serum
CBA/CaH and BALB/c mice were immunised either sys-
temically or orally with the three strains of yeast as described
above. Blood was obtained by direct heart puncture on weeks
2, 5 and 8 after systemic infection, and on weeks 1, 3, 5 and 8
after oral infection. Sera were collected by centrifugation of
blood at 14,000 rpm for 15 min at 4 C. Sera from mice
infected with the same yeast strain were pooled and stored
at 20 C until used.
2.8. Antibody detection
The ECL antibody detection kit (Amersham, USA) was
used. Briefly, the membranes were treated with blocking buffer,
and washed three times with PBS-T. The membranes were
incubated with the appropriate mouse serum, and detected by
incubation with horseradish peroxidase (HRPO)-labelled
IgG1, IgG2a and IgM goat anti-mouse conjugates (CALTAG,
Burlingame, CA, USA) for 1 h at room temperature. The mem-
branes were washed three times, and bands detected with ECL
reagents and ECL Hyperfilm. The films were converted to
digital images with a Nikon Coolpix 995 digital camera (Nikon
Co, Japan) and analysed using Quantity One Software
(Bio-Rad, USA).
2.9. Statistics
All quantitative data were analysed using one-way analysis
of variance (ANOVA) and Student’s t-test, as implemented in
GraphPad Prism Version 2.01 (GraphPad Inc., San Diego, CA,
USA).
3. Results
We have previously noted that mice infected systemically
with yeast strain SC5314 showed a dramatically different pat-
tern of mortality when compared with strain 3630, routinely
used in our laboratory. Deaths resulting from systemic infec-
tion with 3  105 yeasts of strain 3630 typically occurred
within 10 days, after which there was no further mortality
[24]. After infection with the same dose of SC5314, there
was no mortality during this early period, but the long-term
survival rate was very low. Mice began to die at about
20 days, and deaths continued for several months.
3.1. Systemic infection
The virulence of three different isolates of C. albicans,
3630, 3683, and SC5314, was compared by determining the
levels of infection in brain and kidney of ‘tissue susceptible’
(CBA/CaH) and ‘tissue resistant’ (BALB/c) mice after intrave-
nous challenge. In BALB/c mice, infection with 3630 pro-
duced the highest fungal burden in the brain (Fig. 1),whereas infection by SC5314 was significantly less severe.
Using this latter strain of yeast, a substantial proportion (5/
9) of the animals failed to demonstrate infection of the brain.
It should be emphasised that this was not an artefact of inoc-
ulation, as the kidneys of these mice were colonised at levels
not significantly different to other mice in the group, and
doubling the challenge dose (to 6  105) did not increase the
proportion of animals whose brains became infected (data
not shown). SC5314 caused the most severe infection in the
kidney, whereas infections caused by the other two Candida
strains were comparable in severity.
In CBA/CaH mice, the SC5314 strain was most virulent,
showing the highest fungal burden in the kidney (Fig. 2). In
only one case (1/9) did this yeast fail to infect the brain, and
when this animal was excluded, the severity of infection was
equivalent to that induced by 3630. Yeast 3683 was signifi-
cantly less virulent for both organs. When infected with
3630, the fungal burden in the kidney of CBA/CaH mice
was significantly higher compared to that in BALB/c
(4.16  0.17 vs. 3.13  0.51, P < 0.05). However, both the
brain and kidney of CBA/CaH mice were more susceptible
to infection with SC5314 compared to BALB/c mice (brain:
4.15  0.05 vs. 2.06  0.52, P < 0.001 and kidney: 5.93 
0.27 vs. 4.73  0.24, P < 0.01).
Tissue lesions that developed following systemic challenge
with SC5314 were comparable to those previously described
after infection with 3630, and were more severe in CBA/CaH
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Fig. 1. Fungal burden in brain (A) and kidney (B) of BALB/c mice 4 days after
systemic infection with 4  104 Candida albicans 3630, 3683 or SC5413. Bars
represent mean  SEM log10 CFU/g of tissue for a minimum of 7 mice/group.
**P < 0.01, ***P < 0.001.
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tissue susceptibility in the host was independent of Candida
virulence.
3.2. Oral infection
In oral infection, there was a strong interaction between the
yeast and host, that was not seen in systemic infection. In
BALB/c mice, yeast 3683 caused a more severe infection
(P < 0.05) of slightly longer duration than either 3630 or
SC5314 (Fig. 3A). The latter failed to infect the oral cavity
in 4/7 of the mice. In the CBA/CaH mouse strain, the level
and duration of infection by 3683 and 3630 were equivalent.
As in BALB/c mice, SC5314 produced detectable infections
in only 5/10 mice (Fig. 3B). Nevertheless, the relative suscep-
tibility of CBA/CaH and BALB/c mice was similar to that after
systemic infection, in that CBA/CaH mice developed signifi-
cantly more severe infections than did BALB/c mice after
oral inoculation with either strain 3630 or 3683 but not
SC5314. The apparent lack of virulence expressed by
SC5314 after oral challenge was further evaluated by inocula-
tion into BALB/c nude mice, which are acutely susceptible to
infection with strain 3630 [23]. In 2/5 mice, the infection failed
to take, and although oral colonisation persisted significantly
longer in athymic mice than in euthymic controls, it was
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Fig. 2. Fungal burden in brain (A) and kidney (B) of CBA/CaH mice 4 days
after systemic infection with 4  104 Candida albicans 3630, 3683 or
SC5413. Bars represent mean  SEM log10 CFU/g of tissue for a minimum
of 7 mice/group. **P < 0.01, ***P < 0.001.mild in nature (maximum mean score, 2.3  0.3 SEM at
day 4), and decreased during the 21-day period of observation.
3.3. Protection against systemic infection
In the following experiments, BALB/c and CBA/CaH mice
were immunised with the three strains of C. albicans, and
challenged with the homologous and heterologous strains
5 weeks later. The protective effect of immunisation against
challenge with the homologous yeasts is shown in Table 1.
Immunisation of CBA/CaH mice induced strong protective
responses in both brain and kidneys, whereas the response
induced in BALB/c mice varied with the yeast strain used
for immunisation. Isolate 3630 protected the brain but not
the kidneys, whereas in mice immunised with SC5314, the
pattern was reversed. After infection with 3683, protective
responses were only demonstrated in the brain of CBA/CaH
mice, but the kidneys in the CBA/CaH showed no protective
effect, whereas infection in the kidney of BALB/c mice was
significantly enhanced.
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Fig. 3. Oral infections with three strains of yeasts in BALB/c (A) and CBA/
CaH (B) mice. Data points represent the score (mean  SEM) for a minimum
of 7 mice/time point in each group. There was a significant difference between
3683 and 3630 (A), and between SC5314 and 3683 or 3630 (B) on days 4 and 8.
*P < 0.05.
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Protective effect of systemic immunisation against challenge with the homologous yeasts
Mouse strain Treatment Yeast strain
3630 3683 SC5314
Brain Kidney Brain Kidney Brain Kidney
BALB/c Na€ıve 3.7  0.1 5.0  0.2 1.8  0.1 2.6  0.1 2.1  0.5 4.2  0.6
Immunised 2.3  0.3*** 4.4  0.3 1.6  0.2 4.0  0.7* 1.7  0.2 1.8  0.3*
CBA/CaH Na€ıve 4.5  0.2 5.8  0.2 2.7  0.1 2.9  0.2 4.1  0.5 5.9  0.3
Immunised 3.0  0.2** 4.0  0.4*** 1.9  0.2** 3.3  0.5 1.5  0.1** 2.8  0.4***
The data represent the mean  SEM of the log10 CFU/g in tissue, calculated from at least 7 mice for each group. *P < 0.05; **P < 0.01; ***P < 0.001.In general, infection with any one yeast strain failed to pro-
tect against heterologous challenge (Table 2), although some
protection was noted in the kidneys but not the brain of
CBA/CaH mice after immunisation with isolate 3630 and
challenge with SC5314.
3.4. Protection against oral infection
BALB/c and CBA/CaH mice were immunised by oral in-
fection with the three strains of yeasts, and the level of protec-
tion induced was evaluated by oral challenge with yeast strain
3630 five weeks later (Fig. 4). In contrast to systemic chal-
lenge, similar levels of protection were induced in CBA/CaH
mice, regardless of the strain of yeasts used for immunisation,
whereas BALB/c mice were not protected. However, when the
mice were challenged with 3683, only immunisation with the
homologous yeast induced significant protection (Fig. 5).
3.5. B-cell epitope recognition
BALB/c and CBA/CaH mice were immunised with each
of the three strains of C. albicans, and the serum tested for
reactivity against antigenic preparations from the same three
strains. Following systemic immunisation, specific antibody
production was detectable at 2 weeks after immunisation
(data not shown), and the strength of the antibody response
appeared to reach a plateau within 5e8 weeks after infection.
CBA/CaH mice produced antibody of both IgG1 and IgG2a
Table 2
Protective effect of systemic immunisation against challenge with the heterol-
ogous yeasts
Yeast used for: Mouse strain
BALB/c CBA/CaH
Primary
infection
Challenge Brain Kidney Brain Kidney
3630 SC5314 1.9  0.7 3.9  1.0 2.7  0.1 4.3  0.4*
None SC5314 2.1  0.5 4.2  0.6 4.1  0.5 5.9  0.3
3630 3683 1.4  0.1 2.5  0.2 1.9  0.2 4.1  0.5
None 3683 1.8  0.1 2.6  0.1 2.7  0.1 2.9  0.2
SC5314 3630 2.9  0.2 4.6  0.2 3.6  0.3 5.9  0.2
3683 3630 2.9  0.2 4.5  0.3 3.5  0.5 5.4  0.4
None 3630 3.7  0.1 5.0  0.2 4.5  0.2 5.8  0.2
The data represent the mean  SEM of the log10 CFU/g in tissue, calculated
from at least 7 mice for each group. *P < 0.05.subclasses, to a wider range of antigenic determinants than
did BALB/c mice, which produced predominantly IgG1
(Fig. 6). No IgM reactivity was detected in serum from either
CBA/CaH or BALB/c mice immunised with any of the three
isolates of yeasts (data not shown). BALB/c mice only recog-
nised antigens in the 45e48 kDa group, regardless of the
strain of yeast used for immunisation. Antibodies produced
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Fig. 4. Oral protection in BALB/c (A) and CBA/CaH (B) mice after
oral immunisation with 1  108 yeasts of strains 3630, 3683, or SC5314 C.
albicans, and challenge with the same dose of 3630. Data points represent
the score (mean  SEM) for a minimum of 7 mice/time point in each group.
*Significant difference (P < 0.05) between (3683 þ 3630) and the na€ıve group
on day 1; **Significant difference (P < 0.01) between both (3630 þ 3630) and
(3683 þ 3630) compared to the na€ıve group on day 4, and all three groups
compared to the na€ıve group on day 8.
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range, and a lower intensity of recognition than those elicited
by systemic immunisation (data not shown).
4. Discussion
Establishing satisfactory criteria to define the virulence of
C. albicans has been the subject of considerable debate, but
the gold standard must be colonisation and infection in vivo.
Yeast strain 3630, routinely used in our laboratory, has been
shown to establish reproducible infections in the brain, kidney
and other tissues of inbred mice [25], and in the oral cavity [7].
The present experiments have confirmed these results, and
further shown that yeast 3683, derived from an oral infection,
was more efficient in infecting the oral mucosa, while retain-
ing an ability to establish consistent systemic infections. In
contrast, yeast SC5314, from a systemic infection, induced
a very severe infection in the kidney, but was quite inefficient
in infecting either the brain or the oral cavity.
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Fig. 5. Oral protection in BALB/c (A) and CBA/CaH (B) mice after oral
immunisation with 1  108 yeasts of strain 3630 or 3683, and challenge with
the same dose of strain 3683. Data points represent the score (mean  SEM)
for a minimum of 7 mice/time point in each group. Significant difference
between the immunised group and the controls at *P < 0.05 or **P < 0.01,
respectively.
Virulence in vivo has been associated with differences in
proteinase production. Type I strains of C. albicans, that could
invade the chorioallantoic membrane (CAM), were able to
produce proteinase, whereas type II strains that were not
able to penetrate the CAM did not secrete the enzyme [26].
Kidney tissues of mice infected with the type I strains demon-
strated extensive invasion by fungal cells, whereas fungal cells
were rarely found in those infected with the type II strains
[27]. Thus, the inefficiency with which yeast SC5314 infects
the brain and oral cavity suggests that this strain may show
reduced expression of an enzyme essential for attachment to ei-
ther epithelial or endothelial cells. Nevertheless, in a model of
contact lens-facilitated keratitis in rabbits, C. albicans SC5314
penetrated deeper into the cornea than did another clinical
isolate [11], indicating that mechanisms of adherence and/or
invasion by the yeast may be highly specific for different tissues.
Establishment of an oral infection, in particular, has been
associated with expression of SAP1, SAP3, SAP4, SAP7,
and SAP8 [28], whereas SAP2 and SAP5 were present in
both patients with asymptomatic Candida carriage and in
those with oral disease. Thus, comparison of SC5314 and
3683 may be useful in correlating proteinase production
with the efficiency of yeast infectivity at various body sites.
Fig. 6. Western blot showing reactivity of IgG1 (upper panel) and IgG2a (lower
panel) in sera from CBA/CaH and BALB/c mice 5 weeks after systemic infec-
tion with C. albicans 3630. Lane 1, molecular weight standard; lanes 2e4,
antigen preparations of C. albicans 3630, 3683 and SC5314 reacted with
sera from CBA/CaH mice; lanes 5e7, the same preparations reacted with
sera from BALB/c mice.
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yeast to epithelial cell walls is promoted by fungal wall com-
ponents such as mannose, C3d receptors, mannoprotein, and
saccharins [29e31], as well as hydrophobicity [32] and the
ability to bind to host fibronectin [33]. Therefore, virulence
may be a global property of the yeast, representing contribu-
tions from numerous different factors [34]. The yeast may
also demonstrate considerable genetic plasticity, compensating
for reduced function of one gene by the up-regulation of others
not normally expressed [35].
A significant finding from this series of experiments was the
specificity of protection elicited after immunisation with any
particular isolate of C. albicans. Mouse strain specificity in
the expression of antibody-mediated protection has previously
been reported [36], in that immunisation with C. albicans 3630
induced a strong protective response against systemic chal-
lenge in CBA/CaH mice, but not in BALB/c mice, but iso-
late-specific protection was unexpected. This result suggests
that the dominant B-cell epitopes expressed by the various
yeast isolates are significantly different. In only one case was
cross-protection observed, and this was restricted to the kidney.
Inbred mice differ not only in their susceptibility or resis-
tance to C. albicans infection, but also show a specificity of
organ responsiveness, in that different organs appear to be
protected by different components of the immune system.
For example, neutrophil depletion causes an acute increase
in the susceptibility of the heart and kidney, whereas the brain
is only slightly affected [37]. Thus, antibody may, depending
on its specificity and isotype, act to protect different organsd
in BALB/c mice, the brain but not the kidney, and the kidney
but not the brain after immunisation with SC5314. After
immunisation and re-challenge with 3683, both strains of
mice demonstrated enhanced infection in the kidney, while
simultaneously exhibiting protective responses in the brain.
Macrophages from both BALB/c and CBA/CaH mice demon-
strated a depressed killing of 3683 opsonised with homologous
immune serum (see accompanying paper), so the different
responses of brain and kidney may reflect a predominance of
these cell types in protection of the kidney, whereas microglia
may be the major effector cell in defence of the brain.
After oral infection, the situation appears even more compli-
cated. Immunisation with any of the three isolates protected
CBA/CaH, but not BALB/c mice, against challenge with
3630, whereas protection against challenge with 3683 could
only be induced by immunisation with the homologous yeast.
One possible explanation may be the persistence of mannans
or mannoproteins of 3630 in the oral mucosa, that act to induce
a continuing low level of activation in the resident macro-
phages. This activation may then manifest as cross-protection.
An alternative is that there are functional differences between
dendritic cells of the oral cavity and the spleen in processing
of the yeast antigens. In vitro, dendritic cells have been re-
ported to discriminate between yeast and hyphal forms of C.
albicans, producing IL-12 and priming for Th1 cell responses
after contact with the yeast form, whereas contact with hyphae
induced IL-4 production and inhibited IL-12 and Th1 priming
[38]. This discrimination could extend to B-cell epitopes ofdifferent yeasts, resulting in different antibody profiles after
oral or systemic priming.
BALB/c mice respond to infection with C. albicans by pro-
ducing antibodies, predominantly of the IgG1 isotype, against
a restricted range of epitopes, whereas CBA/CaH mice make
antibodies of both IgG1 and IgG2a isotypes, against a much
more diverse spectrum of antigens. In the present experiments,
the general patterns in BALB/c and CBA/CaH mice were con-
sistent with those reported [21,39], and were reproduced after
infection with each of the three yeast strains used in this study.
There were, however, marked differences both between iso-
types, between yeast strains, and between routes of immunisa-
tion, in the antibody profiles elicited. After infection with
3630, IgG2a of CBA/CaH mice recognised the largest number
of different specificities, many not present in the other two
yeast strains, but the IgG1 isotype also detected numerous sep-
arate and non-overlapping specificities. A similar pattern was
seen after infection with 3683, whereas the profiles elicited by
infection with SC5314 were similar for both IgG1 and IgG2a
isotypes. In contrast, only one major reactivity, most probably
against the enzyme enolase [21,39], was detected in the
responses of BALB/c mice to the three strains of Candida.
After immunisation with live C. albicans 3630, both CBA/H
and BALB/c mice show increased resistance to infection;
however, the tissue-susceptible CBA/H mice develop much
stronger protective responses than do tissue-resistant BALB/c
mice [40]. This protection was also evident after infection
with strains 3683 and SC5314, and correlated with the diverse
antibody reactivity generated by this mouse strain. Surprising-
ly, many of the major antigenic reactivities reported in clinical
studies, such as those against proteins of molecular mass
29 kDa, 36 kDa [41], 58 kDa [41,42], 70 kDa [43], and the
90 kDa heat shock protein [44], were not identified in these
mice, although the range of antigens detected was not as exten-
sive as that reported by Pitarch et al. [39], possibly because of
the sensitivity of the two-dimensional gel electrophoresis used
in their study.
In contrast, BALB/c mice showed a restricted range of an-
tibody responses, predominantly to antigens of 45e48 kDa.
Although immunisation with purified proteins, such as eno-
lase, that migrate with this group, stimulates humoral and
cell-mediated immune responses [45], either the limited anti-
body diversity in BALB/c mice is inadequate to confer signif-
icant protection, or BALB/c mice have a high level of innate
resistance against C. albicans infection, and the protective
effect of the antibodies are only evident in specific yeast/organ
combinations. Nevertheless, it seems clear that each of the
yeast strains possesses a relatively distinct antigenic profile,
and that protective responses may involve contributions from
numerous distinct antigenic entities.
It was noted that the pattern of epitopes recognised after
infection of the oral cavity differed from those elicited by
systemic immunisation, although again, the patterns for each
of the yeasts are almost non-overlapping. Two explanations
seem tenable. First, the virulence factors expressed by the yeast
in colonisation and invasion of the oral cavity may be substan-
tially different from those expressed in systemic infection,
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yeast by antigen-presenting cells (APC) in the lymph nodes
draining the oral mucosa may be different to that of splenic
APC. The use of techniques for the generation of antibody
responses in vitro may be necessary to resolve these points.
Although the tissue susceptibility of inbred mouse strains
is comparable in oral and systemic infection, patterns of oral
colonisation by the three yeast isolates differed from tissue
infection in systemic disease, a result consistent with the
hypothesis [15] that the mechanisms of host recovery from
oral and systemic candidiasis may be separate and distinct.
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